Cullinan Therapeutics (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.
The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.
The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.
The company said it expects to start the study in Q2.
Shares of Cullinan were up 2.4% in recent trading.
Price: 7.94, Change: +0.19, Percent Change: +2.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。